Filing Flows › Health Care › Generate Biomedicines (GENB)
Generate Biomedicines (GENB) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 6, 2026 · Generate Biomedicines (GENB) Q2 2026 earnings results →
Q2 2026 Revenue down 38% year over year to $6.3M
Generate Biomedicines made $6.3M in Q2 2026 (-38% Y/Y). Operating margin n/m, net loss $67.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $6.3M in Q2 2026, down 38% year over year and down 13% from the previous quarter.
Operating costs exceeded revenue by $71.6M, an operating margin of -1134.2%. Total costs grew 11% against a revenue fall of 38%. The fastest-growing cost line was General & admin (+29%). The quarter ended with a net loss of $67.3M, wider than the previous quarter's $61.7M loss.
Operating cash flow was −$57.9M. Non-cash charges added back $3.2M of depreciation and amortization and $8.2M of share-based compensation. Capital expenditures of $933K exceeded it, leaving free cash flow of −$58.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 6, 2026 | $6.3M | -38% | n/m | −$67.3M | −$57.9M |
| Q1 2026 | 10-Q | May 7, 2026 | $7.2M | -18% | -887.5% | −$61.7M | −$80.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Generate Biomedicines
Generate (NASDAQ: GENB) is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, and medicine, advancing a new era of programmable biology to engineer better medicines for patients, faster. The Generate Platform integrates computational design with large-scale biological experimentation, enabling the creation of novel, optimized therapeutics that address historically undruggable and hard-to-drug targets, as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded in 2018, Generate is leading a fundamental shift from drug discovery to drug generation.
In its own words, from its 8-K, filed Aug 6, 2026.
Generate Biomedicines against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -38% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| GENB Generate Biomedicines | Q2 2026 | $6.3M | -38% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Generate Biomedicines 10-Q on SEC EDGAR · CIK 2100782 · Pharmaceutical Preparations
13F: who owns GENB and who is buying
More on GENB
- How Generate Biomedicines makes money: revenue by segment
- Generate Biomedicines next earnings date and what analysts expect
- Generate Biomedicines stock forecast, price target and fair value
- Who owns Generate Biomedicines stock: holders, funds and Congress trades
- Generate Biomedicines recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results